Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials

Arthritis and Rheumatism

Volumn 65, Issue 6, 2013, Pages 1586-1591

  Wofsy, David ^a   Hillson, Jan L ^b   Diamond, Betty ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE;

ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GLOMERULUS FILTRATION RATE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

DOUBLE-BLIND METHOD; GLOMERULAR FILTRATION RATE; GLUCOCORTICOIDS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; OUTCOME ASSESSMENT (HEALTH CARE); PROTEINURIA; TREATMENT OUTCOME;

EID: 84878421687     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37940     Document Type: Article

References (8)

1. Wofsy D, Hillson JL, Diamond B,. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; 64: 3660-5.
2. Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9. (Pubitemid 16132725)
3. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
4. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
5. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al, for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
6. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
7. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-4.
8. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ,. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53.